Status:
COMPLETED
Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients
Lead Sponsor:
AbbVie
Conditions:
Hidradenitis Suppurativa
Eligibility:
All Genders
18-99 years
Brief Summary
The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 mont...
Eligibility Criteria
Inclusion
- Diagnosis of Hidradenitis Suppurativa
- Prescribed Adalimumab according to the Summary of Product Characteristics (SmPC)
- Willingness to sign and date a Patient Information/Informed Consent Form
Exclusion
- Prior biologic treatment discontinued \<6 months before the baseline visit
- Patient not able to understand the language of the provided patient questionnaires
- History of non-compliance with medication or a medical history that could enhance non-compliance with medication, as determined by the investigator
Key Trial Info
Start Date :
April 7 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 28 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02739828
Start Date
April 7 2016
End Date
March 28 2018
Last Update
August 9 2019
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitetssjukhuset Linköping
Linkoping, Västra Götaland County, Sweden, 581 85
2
Hallands Hospital Halmstad
Halmstad, Sweden, 301 85
3
Blekinge Hospital
Karlskrona, Sweden, SE-37185
4
Skaraborgs Hospital
Skövde, Sweden, 541 85